Oxytocin has been linked to social behavior, including social recognition, pair bonding and parenting, but its potential role in promoting neuronal growth has not been investigated. We show here that oxytocin, but not vasopressin, stimulates both cell proliferation and adult neurogenesis in the hippocampus of rats. Oxytocin is also capable of stimulating adult neurogenesis in rats subjected to glucocorticoid administration or cold water swim stress. These findings suggest that oxytocin stimulates neuronal growth and may protect against the suppressive effects of stress hormones on hippocampal plasticity. V
INTRODUCTION
Oxytocin is a neuropeptide, released both peripherally and centrally, that has been linked to social behaviors such as mating and parenting (Young and Wang, 2004; Shelley et al., 2006; Carter et al., 2008; Neumann, 2009 ). Oxytocin has also been shown to buffer against some of the negative effects of stress (Windle et al., 2004 (Windle et al., , 2006 Cohen et al., 2010) -its actions include a reduction in hypothalamic-pituitary adrenal (HPA) axis activity and diminished stress-induced activation of brain regions associated with the HPA axis, including the hippocampus.
Oxytocin enhances hippocampal synaptic plasticity and cognitive functions of mother rats (Tomizawa et al., 2003) , but its overall influence on this brain region remains unexplored. The hippocampus is a site of structural plasticity, undergoing neurogenesis throughout lifeevidence has linked cognitive, anxiety and stress regulation functions of the hippocampus to adult neurogenesis . Oxytocin neurons in the hypothalamic paraventricular nucleus project to various brain regions, including the hippocampus (Bujis and Swaab, 1979; Sofroniew, 1983) . Oxytocin receptors are present in the hippocampus where they are more concentrated in the ventral than dorsal region and subject to modulation by stress and glucocorticoids (Liberzon and Young, 1997) .
Oxytocin has been shown to affect cell proliferation in peripheral systems, exhibiting stimulatory effects on blood cells, osteoblasts, and some types of tumor cells (Petersson, 2008; Macciò et al., 2010) as well as inhibitory effects on prostate and mammary cells (Sapino et al., 1998; Whittington et al., 2007; Petersson, 2008) , but its ability to influence neuronal growth in the brain remains unexplored. Since stress and glucocorticoids can be potent regulators of cell proliferation and adult neurogenesis in the hippocampus (Mirescu and Gould, 2006; and oxytocin is known to attenuate stress responses (Windle et al., 2004 (Windle et al., , 2006 , we investigated whether oxytocin alters adult neurogenesis and whether this effect occurs in the presence of elevated glucocorticoids. Here we show that peripheral and central oxytocin, but not the closely related neuropeptide vasopressin, enhances cell proliferation and adult neurogenesis. The stimulatory effect of oxytocin on cell proliferation occurred even in rats treated with glucocorticoids or exposed to a stressor. These findings raise the possibility that oxytocin acts to protect the hippocampus from the damaging effects of elevated glucocorticoids by promoting neuronal growth.
MATERIALS AND METHODS

Animals
Adult ( 60 days of age) male Sprague-Dawley rats (Taconic; Germantown, NY) were provided unlimited access to food and water and maintained on a 12:12 light-dark cycle (lights on at 7:00 a.m.). Rats were group-housed (2-3/cage) and all rats within a cage were included in the same experimental group. Procedures were conducted in accordance with Princeton University IACUC and The National Institutes of Health Guide for the Care and Use of Laboratory Animals.
bromodeoxyuridine (BrdU; 200 mg/kg; Sigma, St. Louis, MO), a dose that labels the maximal number of S phase cells in the dentate gyrus (DG) (Cameron and McKay, 2001) . Rats were perfused 2 h later, a post-BrdU survival time that is sufficient to label cells in S-phase but not to allow the labeled cells to divide, thus providing a measure of cell proliferation. Additional groups of rats (n 5 10-11/group) were injected i.p. with 1 mg/kg oxytocin, 30 min later injected i.p. with BrdU and perfused after one week or three weeks. At one week, the number of BrdU-labeled cells is at its maximum and most express markers of immature neurons . By three weeks post-BrdU labeling, the majority of new cells in the DG express the mature neuronal marker NeuN. A final group of rats (n 5 6-9/group) was injected i.p. with 1 mg/kg oxytocin or an equal volume of saline once daily for seven consecutive days. On the last day, rats were injected with BrdU 30 min following the oxytocin or saline injection and perfused three weeks later.
Peripheral Vasopressin
Rats (n 5 4-5/group) were injected i.p. with arginine vasopressin (10 lg/kg; Sigma) or an equal volume of saline. This dose was chosen based on previous studies of i.p. injections of vasopressin in rats (Izquierdo et al., 1988) . Thirty minutes later, all rats were injected with BrdU and perfused after 2 h.
Central Oxytocin
Rats (n 5 11) were anesthetized with Nembutal and restrained in a stereotaxic apparatus. Using a 26 gauge Hamilton syringe, rats received hippocampal injections of oxytocin (1 ng/1 ll; Sigma; dose based on Melis et al., 1997; Ring et al., 2006) in one hemisphere and an equal volume of saline (1 ll) in the other hemisphere (stereotaxic coordinates: AP, 25.3 from Bregma; LM, 6 4.0; DV, 23.5 from surface of brain; Paxinos and Watson, 1998) . Prior studies have shown that injection volumes of 2 ll do not produce degeneration in the granule cell layer (Gould and Tanapat, 1997) . The injections in each hemisphere were counter-balanced and the hemispheres were analyzed separately. Thirty minutes later, rats were injected with BrdU and perfused after a 2 h survival time.
Oxytocin and Corticosterone
Rats (n 5 12) were given an i.p. injection of oxytocin (1 mg/kg; Bachem) and thirty min later were subcutaneously injected with 40 mg/kg corticosterone (Sigma), a dose that has been previously shown to diminish cell proliferation in the DG (Cameron and Gould, 1994 ). An additional group of rats (n 5 14) was injected with saline followed by corticosterone. One hour later, both groups of rats were injected with BrdU and perfused after a 2 h survival time.
Oxytocin and Cold Swim Stress
Rats (n 5 11) were given i.p. injections of oxytocin (1 mg/kg; Bachem) and then thirty min later exposed to a cold water (2-68C) swim stress for three min. This stressor has been shown to diminish cell proliferation in the DG (Stranahan et al., 2006 ). An additional group of rats (n 5 13) was exposed to the cold water swim stress following treatment with saline. This procedure was repeated once daily for seven consecutive days. On the last day, rats were injected with BrdU 1 h following the oxytocin or saline injection and perfused after a 2 h survival time.
Perfusion
All animals were deeply anesthetized with an overdose of sodium pentobarbital and transcardially perfused with 4.0% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were removed and postfixed for at least two days.
Immunohistochemistry
Coronal sections (40 lm thick) throughout the entire rostrocaudal extent of the DG were cut with a Vibratome into a bath of 0.1 M phosphate-buffered saline (PBS). For peroxidase staining, a 1:12 series of sections were mounted onto slides, dried, heated in 0.1 M citric acid, rinsed in PBS, digested in trypsin, rinsed, denatured in 2N HCl:PBS and rinsed. Slides were incubated overnight at 48C in mouse monoclonal antibody against BrdU (1:200; BD Biosciences, San Jose, CA) then rinsed, incubated with biotinylated horse anti-mouse (1:200; Vector, Burlingame, CA), rinsed, incubated with avidin-biotin complex (Vector), rinsed and reacted in 0.01% diaminobenzidine (Sigma) with 0.003% H 2 O 2 . Slides were counterstained with cresyl violet, dehydrated, cleared with Citrisolv (Fisher Scientific) and coverslipped with Permount (Fisher Scientific).
For assessment of cell phenotype, tissue from rats with a three week post-BrdU survival time was processed for doublelabeling immunofluorescence for BrdU and the neuronal marker NeuN or the astroglial marker GFAP. A 1:12 series of free-floating sections were denatured in 2 N HCl: Tris buffered saline (TBS), rinsed in TBS, and incubated with rat anti-BrdU (1:200; Accurate, Westbury, NY) plus mouse anti-NeuN (1:500; Chemicon, Temecula, CA) or guinea pig anti-GFAP (1:1,000; Advanced Immunochemical, Long Beach, CA) for two days at 48C. Sections were then rinsed, incubated with biotinylated anti-rat (Chemicon), rinsed, and incubated with streptavidin-conjugated Alexa 568 (1:1,000; Molecular Probes, Eugene, OR) for BrdU, and with goat anti-mouse or goat antiguinea pig Alexa 488 (1:500; Molecular Probes) for NeuN or GFAP. After rinsing, sections were mounted onto slides and coverslipped using glycerol:TBS (3:1).
Data Analysis
Slides were coded prior to quantitative analysis. For BrdU peroxidase analysis, the number of BrdU-labeled cells in the DG (subgranular zone, granule cell layer and hilus) was counted on every 12th section of tissue at 100x on an Olympus BX-50 light microscope. For experiments with a 2 h sur-vival, BrdU-labeled cells were counted throughout the entire rostrocaudal extent of the DG (2.20-7.20 mm; Paxinos and Watson, 1998) as well as in the dorsal and ventral DG separately (Banasr et al., 2006) . For experiments with one week or three week survival times, BrdU-labeled cells in the dorsal and ventral DG were counted separately. For experiments involving peripheral injections of oxytocin or vasopressin, half brains were analyzed. Counts were multiplied by 24 to obtain bilateral estimates of the number of BrdU-labeled cells per brain. For the central oxytocin study, counts were multiplied by 12 because both sides of the brain (saline and oxytocin) were analyzed separately. Cavalieri's principle (Gundersen et al., 1988) was used for determination of DG volume (hilus and granule cell layer) from cross-sectional area measurements obtained with Image-Pro Plus software (Media Cybernetics, Silver Spring, MD).
For purposes of comparison, the density of BrdU-labeled cells was also determined in the subventricular zone (SVZ). BrdU-labeled cells in the SVZ present on every twelfth coronal section throughout the DG were counted, the volume of the analyzed region determined, and the data expressed as densities (number of BrdU-labeled cells/mm 3 ). For BrdU immunofluorescence, the percentage of BrdUlabeled cells in the granule cell layer and subgranular zone expressing NeuN or GFAP was determined using a Zeiss Axiovert confocal laser scanning microscope (510 LSM; lasers, Argon 458/488 and HeNe 543; Zeiss, Oberkochen, Germany). Dorsal and ventral DG were analyzed separately as described above. For each brain, marker, and subregion, 15-25 randomly selected BrdU-labeled cells were analyzed. Optical stacks of 1-lm thick sections were obtained through putative doublelabeled cells. To verify double labeling throughout their extent, cells were examined in orthogonal planes.
Statistical analyses
Unpaired t-test or one-way analysis of variance (ANOVA) followed by Newman-Keuls post hoc comparisons were used to analyze differences in the number of BrdU-labeled cells in the DG (total, dorsal, ventral), BrdU-labeled cells in the subventricular zone, the volume of the DG, and the volume of damage in the granule cell layer caused by the central injections of oxytocin and saline. When animals were given central injections, paired t-tests were used because the other side of the brain (salineinjected) served as a control for the oxytocin-injected side.
RESULTS
Acute Peripheral Oxytocin Administration Enhances Cell Proliferation in the Ventral DG
To assess the effects of acute oxytocin administration on cell proliferation, animals were given a single peripheral injection of oxytocin, injected with BrdU 30 min later and perfused after a 2 h survival time. A single injection of oxytocin enhanced cell proliferation in the DG (F(2,23) 5 4.49 -P < 0.05). Analysis of dorsal and ventral DG separately revealed that the increase was evident only in the ventral DG (F(2,23) 5 10.02 -P < 0.005; Fig. 1 ). Rats given 1 mg/kg oxytocin had more BrdU-labeled cells than rats given saline or a higher dose of oxytocin (10 mg/kg). Groups given saline or 10 mg/kg oxytocin did not differ in dorsal, ventral or dorsal-ventral combined (P > 0.05) To determine whether these effects are specific to oxytocin, an additional group of animals was injected with the closely related neuropeptide vasopressin (AVP), injected with BrdU after 30 min and perfused 2 h later. Unlike oxytocin, AVP had no significant effect on the number of proliferating cells in the Using the same single dose of oxytocin (1 mg/kg) that enhanced cell proliferation, we found that the number of BrdU labeled cells was no longer increased at later time points after BrdU injection. One week and three weeks after BrdU administration, there was no difference in the number of BrdU-labeled cells in the dorsal, ventral or dorsal-ventral combined DG in groups treated with saline or 1 mg/kg oxytocin (P-values >0.05).
Repeated Peripheral Oxytocin Increases the Number of New Neurons
We next examined whether more sustained exposure to oxytocin would produce a lasting enhancement in the number of BrdU labeled cells by using a repeated oxytocin injection paradigm. Male rats were given seven days of oxytocin injections, a BrdU injection on the last day, and perfused three weeks later. Compared with saline-treated controls, rats treated with oxytocin had more BrdU-labeled cells in the ventral DG (t(12) 5 2.18 -P < 0.05; Fig. 3a) . The number of BrdU-labeled cells in the dorsal DG did not differ between saline and oxytocin treated groups (P > 0.05). Most (88%) BrdU-labeled cells expressed the marker of mature neurons, NeuN (Fig. 3b) . A small percentage (5%) expressed the astroglial marker, GFAP (Fig. 3c) . There was no difference in the proportion of BrdU-labeled cells expressing these markers across groups or subregions (P-values > 0.05). No differences in the total volume of the dentate gyrus were detected among the groups (Saline: 11.78 6 0.24, Oxytocin: 11.87 6 0.49 -P > 0.05). No differences were detected in the volume of the dentate gyrus at dorsal (Saline: 6.25 6 0.41, Oxytocin: 5.68 6 0.22 -P > 0.05) or ventral (Saline: 5.53 6 0.28, Oxytocin: 6.19 6 0.30 -P > 0.05) levels. Taken together, these data suggest that repeated oxytocin injection enhanced the number of adult-generated cells for at least three weeks, including both neurons and glia. Chronic peripheral oxytocin enhances adult neurogenesis. Rats received an i.p. injection of OT (1 mg/kg) or an equal volume of saline once daily for seven consecutive days. All animals were injected with BrdU 30 min after the last injection and perfused after a three-week survival. (a) Chronic OT increased the number of BrdU-labeled cells in the ventral, but not dorsal, DG. Bars represent mean 6 SEM, *P < 0.05. At this time, most BrdU-labeled cells (red) in the saline and OT groups were co-labeled with (b) the mature neuronal marker NeuN (green) but not with (c) the astroglial marker GFAP (green). Scale bar, 10 lm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Central administration of oxytocin enhances cell proliferation. Adult male rats received hippocampal injections of OT (1 ng/ll) in one hemisphere or an equal volume of saline into the other hemisphere. All animals were injected with BrdU 30 min later and perfused after a 2-h survival. The hemisphere treated with OT had a greater number of BrdU-labeled cells in the ventral DG compared to the saline-treated hemisphere. The number of BrdU-labeled cells in the dorsal DG did not differ between the saline and OT treated hemispheres. Bars represent mean 6 SEM, *P < 0.05. Photomicrographs show more BrdU-labeled cells (brown cells) in the ventral DG of rats treated with OT. Scale bar, 10 lm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Hippocampal Oxytocin Enhances Cell Proliferation
We next evaluated whether oxytocin acts directly within the hippocampus to alter cell proliferation. Rats received hippocampal microinfusions of oxytocin in one hemisphere and saline in the other, allowing the other side of the brain of each animal to serve as its own control. Thirty minutes after the infusion, rats were injected with BrdU and perfused after a 2 h survival time. We found that the hemisphere treated with oxytocin had a significantly greater number of BrdU-labeled cells in the ventral DG than the saline-treated hemisphere (t(10) 5 2.69, -P < 0.05 Fig. 4) . The number of BrdU-labeled cells in the dorsal DG was unaffected by OT (P > 0.0.5). These regional differences were not due to variations in the area of damage in the DG at the injection site which was similar for the saline-and oxytocin-treated hemispheres (P > 0.05).
Oxytocin Enhances Cell Proliferation in Animals Treated With Corticosterone or Exposed to Swim Stress
We next examined whether oxytocin could enhance cell proliferation under conditions associated with increased levels of glucocorticoids. Rats were treated with oxytocin 30 min before receiving a single corticosterone injection (OT + CORT) or with corticosterone alone (CORT). After 1 h, rats were injected with BrdU and perfused after a 2 h survival. Corticosterone treated rats that were also given oxytocin had more BrdU-labeled cells in total DG than animals that did not receive oxytocin (t(24) 5 2.44, -P < 0.05). This difference was concentrated in the ventral hippocampus which showed a significant increase in oxytocin treated animals (t(24) 5 3.52, -P < 0.005; Table 1 ). In the dorsal DG, no difference in the number of BrdU-labeled cells was detected between CORT and OT 6 CORT groups (P > 0.05, Table 1 ). To evaluate the effects of oxytocin on cell proliferation in animal undergoing repeated stress, rats were treated daily with oxytocin and 30 min later exposed to cold water swim stress (OT + Stress) or were exposed to the stressor without OT (Stress). On the seventh day, rats were injected with BrdU one hr after the stressor and perfused after a 2 h survival. Rats that were treated with oxytocin and exposed to cold water swim stress for seven days showed an increase in BrdU labeled cells in the total DG (t(22) 5 2.13 5 2.13 -P < 0.05). However, there was no statistically significant difference in BrdU cell number in either the dorsal (t(22) 5 1.90 -P 5 0.07) or ventral (t(22) 5 1.87 -P 5 0.08) DG (Table 1) .
DISCUSSION
Here we show that acute administration of oxytocin, either centrally or peripherally, stimulates cell proliferation in the DG. Although the proliferative effects of acute oxytocin treatment did not result in an increase in neurogenesis at one week or three weeks, more prolonged treatment of oxytocin (i.e., one week of daily peripheral oxytocin injections) increased neurogenesis, an effect that appears to be specific to the ventral portion of the DG. In addition, we show that the stimulatory effect of oxytocin on cell proliferation occurred even in rats treated with glucocorticoids or exposed to stress. Taken together, these results suggest that oxytocin stimulates neuronal growth and may protect against the suppressive effects of stress hormones on hippocampal plasticity.
Although we tested two doses of peripheral oxytocin on cell proliferation, only the lower dose was found to stimulate cell proliferation. In this regard it should be noted that effects of neuropeptides such as oxytocin are often dose-dependent but not always linear. For example, the effects of peripheral oxytocin on social recognition follow an inverted U-shaped dose response curve where moderate doses facilitate, and high doses attenuate social recognition (Popik et al., 1992) . Because we didn't examine doses lower than 1 mg/kg or higher than 10 mg/kg, the exact dose response relationship between oxytocin and cell proliferation remains to be determined.
Only small amounts of oxytocin given peripherally pass through the blood brain barrier (Ermisch et al., 1985; Engelmann et al., 1996) . Nonetheless, a number of studies have shown that either subcutaneous or intraperitoneal administration of OT can trigger many of the same responses that occur following the release of, or administration of, OT within the CNS (Arletti et al., 1992; McCarthy et al., 1992; Petersson et al., 1996) . We also found that like peripheral oxytocin, acute central administration of oxytocin into the hippocampus similarly increased cell proliferation. Taken together, these data suggest that oxytocin is acting within the hippocampus to increase the number of new cells. Oxytocin receptors are known to be expressed in the hippocampus (Liberzon and Young, 1997; Gimpl and Farrenholz, 2001; Tomozawa et al., 2003) further indicating that the hippocampus is a likely target for oxytocin. However, it remains unclear whether the effects of oxytocin on cell proliferation and neurogenesis are mediated via direct activation of oxytocin receptors on precursor cells within the DG. Alternatively, it's possible that oxytocin modulates these processes indirectly by acting on oxytocin-responsive cells within brain regions that provide afferent input to the DG such as the amygdala (Gimpl and Farrenholz, 2001) or through its influence on other hormonal or neurotransmitter systems that have been shown to alter cell proliferation. Oxytocin is known to diminish HPA axis responsiveness and lower levels of circulating glucocorticoids (Windle et al., 2004 (Windle et al., , 2006 Cohen et al., 2010) . Another possible interpretation of our findings demonstrating that oxytocin stimulates cell proliferation and neurogenesis is that it does so by lowering levels of corticosterone. Numerous studies have shown that elevated corticosterone, applied either exogenously or through exposure to aversive stressors, suppresses cell proliferation and neurogenesis (Cameron and Gould, 1994; Tanapat et al., 2001; Mirescu and Gould, 2006) . Conversely, lowering glucocorticoid levels by adrenalectomy enhances cell proliferation and neurogenesis (Gould et al., 1992) . Our results show that oxytocin enhances cell proliferation even after elevating corticosterone levels acutely by injection. These findings suggest that the stimulatory effects of oxytocin on cell proliferation and neurogenesis in the DG are unlikely to be mediated only indirectly through oxytocin-induced reductions in glucocorticoid levels. These findings further suggest the possibility that oxytocin may be capable of overriding some of the negative effects of elevated glucocorticoids, such as those on neuronal growth inhibition. It should be noted, however, that our stress and oxytocin findings were less conclusive than the corticosterone injection study. That is, we observed a statistically significant increase in the number of BrdU labeled cells in the stress plus oxytocin condition only in the overall DG but not within the dorsal or ventral subregions. The lack of a region-specific increase in cell proliferation in oxytocin treated stressed rats suggests that different mechanisms may be operating under this condition compared with following corticosterone injection. In this regard, we cannot rule out some potential involvement of the HPA axis in mediating these effects without additional experimentation.
Nonetheless, it remains possible that oxytocin is responsible for promoting neuronal growth under some circumstances where glucocorticoids are naturally elevated. For example, sexual experience is rewarding yet elevates corticosterone levels and paradoxically promotes cell proliferation and adult neurogenesis . Sexual experience also stimulates oxytocin release in the periphery, as well as in the brain (Stoneham et al., 1985; Carmichael et al., 1987; Waldherr and Neumann, 2007) . Taken together with the present paper, this work suggests that oxytocin may buffer the brain from elevated corticosterone levels during mating by preventing growth inhibition and stimulating neurogenesis. Similarly, oxytocin is released during physical activity (Michelini, 2001) , another rewarding experience which also paradoxically causes an increase in glucocorticoids and an increase in adult neurogenesis (van Praag et al., 1999; Stranahan et al., 2006) . The release of oxytocin during these experiences could provide the mechanism by which the hippocampus is protected from the rise in glucocorticoids.
Although acute peripheral oxytocin injection rapidly increases cell proliferation in the DG, the additional granule cells are lost during the ensuing period of cell death. After daily injection with oxytocin, however, a lasting effect on adult neurogenesis is observed. This increase is specific to the ventral portion of the DG. The ventral hippocampus is connected with the amygdala, the medial prefrontal cortex and HPA axis structures (Sahay and Hen, 2007; Fanselow and Dong, 2010) and is also involved in some types of learning and memory (Dalla et al., 2009; Snyder et al., 2009a) , though it is more generally thought to play a role in anxiety and stress regulation (Herman et al., 1995; Bannerman et al., 2004) . Studies have shown that oxytocin receptors are more abundant in the ventral portion of the hippocampus (Liberzon and Young, 1997) . Thus, the effects of oxytocin on neurogenesis in the ventral hippocampus are consistent with the release of oxytocin in response to certain stressors and the role of the ventral hippocampus in stress regulation.
Although the specific role of adult-born neurons is not yet fully understood, there is a wide body of evidence that adultborn cells start to become integrated into the neuronal circuitry shortly after their production (Hastings and Gould, 1999; Ide et al., 2008; Snyder et al., 2009b) and that these cells are important for hippocampal function, especially anxiety regulation and learning. A reduction in adult-generated neurons in the DG produces deficits in hippocampus-dependent learning (Shors et al., 2001; Leuner et al., 2006; Snyder et al., 2009b) , and learning hippocampus-dependent tasks is impaired under circumstances in which adult neurogenesis is diminished, such as after glucocorticoid administration (Luine et al., 1993; Bodnoff et al., 1995) or negative stress paradigms (Luine et al., 1996; Krugers et al., 1997) . When the number of new neurons in the hippocampus is enhanced by experiences such as living in an enriched environment (Kempermann et al., 1997; Nilsson et al., 1999) or running (van Praag et al., 1999) , performance on these learning tasks is improved. It has also been shown that hippocampal adult neurogenesis is involved in anxiety regulation (Revest et al., 2009) . Therefore oxytocin-induced increases in new neurons in the DG could contribute to the reductions in anxiety and enhancement in learning observed with rewarding experiences. These results taken together show that oxytocin has the potential for protecting the hippocampus from the adverse effects of elevated glucocorticoids and that oxytocin released during certain experiences may have beneficial effects in the hippocampus.
